Search

See sweet to C-suite: Carrie MacEwen

The business world tells us, “Know your why.” But increasingly, we live in a society where people think, “Why bother?” In this interview, David wants to know what makes Carrie MacEwen tick, and why she bothered to get involved locally,...

Viva Las Vegas: Dr Corey Hochman

Speaking with Phoenix-based ophthalmologist and poker player, Dr Corey Hochman, Peter Cackett explores the themes of success and failure, and how the ups and downs of one’s ambition can provide an overwhelming gratitude for life. “Money won is twice as...

Pathophysiology of diabetic macular oedema: why combination therapy may be better

The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...

A look into the IOL space

Advances in the design and performance of intraocular lenses (IOLs) continue to be driven by demand for better outcomes, presbyopia correction and spectacle independence, alongside a better understanding of the dynamics of the crystalline lens, newer theories of accommodation and...

Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease

Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...

The use of toxin in paediatric strabismus

Strabismus is a common condition that affects up to 5% children and can be associated with abnormal visual development, double vision, loss of depth perception and impaired binocularity [1]. It can also cause cosmetic concerns, negatively impact psychosocial wellbeing and...